U.S. Diversified Financial Stock News

Bloom Energy (BE) is in focus after expanding its partnership with Brookfield, lifting available financing for AI power projects from US$5b to US$25b, alongside expectations for stronger upcoming earnings metrics. See our latest analysis for Bloom Energy. Despite the Brookfield expansion and rising interest in AI data center power, Bloom Energy's share price has pulled back sharply in the short term, with 1 day, 7 day and 30 day share price returns all declining, even as the year to date...

Globe Life Inc. ( NYSE:GL ) shareholders are probably feeling a little disappointed, since its shares fell 6.1% to...

Anyone interested in The PNC Financial Services Group, Inc. ( NYSE:PNC ) should probably be aware that the Executive VP...

Elevance Health, Inc. ( NYSE:ELV ) shareholders (or potential shareholders) will be happy to see that the President...

Even though Linkhome Holdings Inc. ( NASDAQ:LHAI ) has fallen by 12% over the past week , insiders who sold US$2.4m...

SiteOne Landscape Supply (SITE) has been trading under pressure recently, with the stock down about 14% over the past month and roughly 30% in the past 3 months from its recent levels. See our latest analysis for SiteOne Landscape Supply. That recent weakness comes on top of a year-to-date share price return of down about 20% and a 1-year total shareholder return of down roughly 25%. This points to fading momentum as investors reassess SiteOne Landscape Supply’s risk and growth profile. If...

Bausch + Lomb has launched its EyeGility Inserter in the U.S., a preloaded intraocular lens delivery system tailored for its enVista Aspire IOLs and, soon, enVista Envy lenses, aiming to offer smoother, one-handed cataract lens implantation through a 2.4mm incision. This new inserter emphasizes surgeon convenience and reliability, with features like balanced push force and extended standby time that could make Bausch + Lomb’s premium IOL platforms more appealing in everyday cataract...

On 20 July 2026, Tutor Perini Corporation (NYSE:TPC) was added to the S&P 1000, S&P Composite 1500, S&P 600, and S&P 600 Industrials indices, broadening its presence across key US equity benchmarks. This wave of index inclusions comes as investors focus on an upcoming earnings report that is expected to show higher revenue but lower earnings per share year-over-year, sharpening attention on the company’s execution and profitability. We’ll now explore how Tutor Perini’s addition to major S&P...

Recently, analysts issued a negative outlook on Ralph Lauren, highlighting weak constant currency revenue growth, suboptimal operating margin, and disappointing free cash flow projections relative to consumer discretionary peers. An interesting twist is that these concerns arise even as Ralph Lauren shows some operating margin improvement, prompting questions about the quality and sustainability of its profitability profile. We’ll now examine how these concerns about weak constant currency...

Grocery bills are staying stubbornly high, even as overall inflation cools, and that is reshaping where and how people shop. Traditional supermarkets face pressure as shoppers hunt for deals, trade down to store brands, and shift more spending toward discounters like Costco and Walmart. At the same time, price rollbacks and elevated input costs are squeezing margins across the sector. This article walks through three stocks that appear particularly exposed to these grocery inflation...

Earlier this week, EPAM Systems was lifted by a broad rally in IT services companies, as investors shifted funds into the sector amid renewed interest in technology-focused outsourcing and engineering providers. At the same time, White Falcon Capital Management flagged EPAM as a recent portfolio drag due to delayed digital transformation projects tied to rapid AI developments, while arguing that the company’s AI engineering strengths could be underappreciated relative to its compressed...

HNI (HNI) stock is in focus after the company was named to the TIME America’s Best Companies 2026 list, spotlighting employee satisfaction, financial performance, and sustainability transparency for investors tracking workplace-focused businesses. See our latest analysis for HNI. HNI's inclusion on TIME’s list comes as the stock trades at $41.62, with a 30 day share price return of 5.07% and a 90 day gain of 10.54%, while the 1 year total shareholder return is down 17.60% and the 3 year total...

First BanCorp (FBP) drew fresh investor attention after reporting second quarter 2026 results, combining lower net charge offs of $15,979,000 with ongoing share repurchases and a reaffirmed quarterly dividend. See our latest analysis for First BanCorp. At a share price of $28.82, First BanCorp has posted a strong year to date share price return of 37.89%, with recent momentum supported by a 18.89% 90 day share price return and a 41.16% 1 year total shareholder return. If First BanCorp's...

Range Resources earnings and buyback move put recent stock action in focus Range Resources (RRC) is back on investors' radar after reporting second quarter 2026 results that showed lower quarterly revenue and net income, in contrast with stronger first half figures and the completion of a multi year share repurchase program. The company posted second quarter revenue of US$833.57 million and net income of US$195.32 million, while also confirming it has retired 35,915,000 shares since 2019,...

IPG Photonics stock has declined by around 58.0% over the past five years, yet the shares still screen as expensive on the valuation checks that are available today. Over five years, IPG Photonics has fallen about 58.0%, which indicates that long term shareholders have faced a significant loss of value. The agreed €300 million acquisition of Lumibird Medical, with a potential €50 million earnout, can support expectations for a broader medical laser platform. However, integration and...

Amgen (AMGN) is back in focus after quarterly revenue of $8.62b surpassed analyst forecasts, with management pointing to double digit growth across 16 brands and reaffirming confidence in its long term outlook. See our latest analysis for Amgen. Against this backdrop, Amgen’s recent momentum has been firm. A 10.54% 90 day share price return and a 26.34% 1 year total shareholder return suggest investors are responding positively to earnings delivery and the company’s pipeline progress. If you...

Nucor Corporation recently announced that it expects stronger second-quarter 2026 segment profits and higher steel selling prices, supported by robust demand in key end markets and cash refunds tied to raw material costs. Beyond the headline profit improvement, Nucor’s diversified exposure across construction, manufacturing and infrastructure appears to be reinforcing confidence in its longer-term growth initiatives despite pockets of softer demand. We’ll now examine how expectations for...

ACADIA Pharmaceuticals (ACAD) drew investor attention after the FDA granted Fast Track designation to its investigational drug remlifanserin for hallucinations and delusions in Alzheimer’s disease psychosis, alongside new timing details for the RADIANT trial program. See our latest analysis for ACADIA Pharmaceuticals. The Fast Track news arrives after a period where ACADIA Pharmaceuticals’ share price has moved in fits and starts. The 90 day share price return of 11.39% contrasts with a year...

SkyWest (SKYW) has just put fresh numbers on the table for Q2 2026, reporting total revenue of US$1.1 billion and basic EPS of US$2.55, with net income of US$100.7 million setting the tone for the quarter. The company has seen quarterly revenue move from US$1.02 billion in Q4 2025 to US$1.01 billion in Q1 2026 and then to US$1.1 billion in Q2 2026, while quarterly EPS shifted from US$2.28 to US$2.54 to US$2.55 over the same stretch. This gives investors a clear view of how the top and bottom...

Amneal Pharmaceuticals recently received U.S. FDA approval for additional strengths and vial sizes of its iohexol injection, a widely used radiographic contrast agent, expanding on its previously approved 300 mg iodine/mL 100 mL vials. By launching the first generic versions referencing OMNIPAQUE across these presentations, Amneal aims for its broadened iohexol portfolio to cover most U.S. demand while offering providers greater flexibility and supply options in imaging procedures. We’ll now...

Western Union (WU) is back in focus after the company announced that Executive Vice President and Chief Legal Officer Benjamin Adams plans to retire under its Voluntary Retirement Program. See our latest analysis for Western Union. Western Union's share price has been under pressure recently, with a 7 day share price return that is down 7.4% and a 90 day share price return that is down 12.3%, even though the 1 year total shareholder return is 7%. This suggests momentum has faded in the short...

In recent weeks, Space Exploration Technologies Corp. has been added to the Nasdaq‑100 Index, even as its shares continued to slide after June’s record‑setting IPO and ahead of its first earnings report on August 4, which will trigger initial insider lock‑up expirations on August 6. At the same time, operational and commercial developments, from Starship test delays to Cebu Pacific’s decision to introduce Starlink inflight Wi‑Fi, highlight how SpaceX’s heavy investment in launch,...

Becton Dickinson (BDX) is back in focus after the company announced that long serving executive Michael D. Garrison plans to retire in October, prompting investors to reassess leadership and segment reporting. See our latest analysis for Becton Dickinson. Becton Dickinson’s share price has been choppy, with a 2.22% 1 day share price gain to US$156.36 and a year to date share price return down 19.79%. The 1 year total shareholder return of 10% indicates dividends and reinvestment have softened...

ACM Research stock has delivered a very large 3 year return while current valuation checks, including an intrinsic value estimate using a Discounted Cash Flow (DCF) approach and market multiples, both point to the shares trading at a premium. ACM Research has returned roughly 7x over the past 3 years. This puts extra focus on whether the current price leaves much margin for error. Expectations for future revenue and cash flow growth can support the current valuation. However, any...